Bromide

Bromide

SCHEMBL1729321

Br.CCOc1cc2c(cc1C(=O)NC)C(=N)N(CC(=O)c1cc(OC)c(OCCCC(N)=O)c(C(C)(C)C)c1)C2

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
F2R P25116 17/20 0.46
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
SLC6A5 Q9Y345 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1732780 0.94 F2R (0.48) F2RKDM4ENPC1MAPTRAB9A
Bromide SCHEMBL1729447 0.94 F2R (0.49) F2RKDM4ENPC1MAPTRAB9A
Bromide SCHEMBL1731565 0.93 F2R (0.46) F2RKDM4ENPC1MAPTRAB9A
Bromide SCHEMBL1731149 0.93 F2R (0.48) F2RKDM4ENPC1MAPTRAB9A
Bromide SCHEMBL1730620 0.92 F2R (0.51) F2RKDM4ENPC1MAPTRAB9A
SCHEMBL12151783 0.91 F2R (0.51) F2RKDM4ENPC1MAPTRAB9A
Bromide SCHEMBL1731831 0.91 F2R (0.45) F2RKDM4ENPC1MAPTRAB9A
Bromide SCHEMBL1732078 0.90 F2R (0.47) F2RKDM4ENPC1MAPTRAB9A
Bromide SCHEMBL5486569 0.90 F2R (0.49) F2RKDM4ENPC1MAPTRAB9A
Bromide SCHEMBL1728702 0.89 F2R (0.54) F2RKDM4ENPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1391451-B1 2-IMINOPYRROLIDINE DERIVATES EISAI R&D MAN CO LTD (JP) 2011-11-23 EP disclosed
US-7244730-B2 2-iminopyrrolidine derivatives EISAI CO., LTD (JP) 2007-07-17 US disclosed
US-20050245592-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-03 US disclosed
US-20050004204-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245592-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 F2R 2290/4885KDM4E 3161/4885NPC1 4243/4885
US-20050004204-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 F2R 2289/4885KDM4E 3132/4885NPC1 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.